prikaz prve stranice dokumenta Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams
Medical Hypotheses, 193 (2024); 111510. https://doi.org/10.1016/j.mehy.2024.111510
Stanić Damić, Marija; Valković, Toni; Petranović, Duška; Belančić, Andrej; Perić, Zinaida

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Stanić Damić, M., Valković, T., Petranović, D., Belančić, A. & Perić, Z. (2024). Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams. Medical Hypotheses, 193.. doi: 10.1016/j.mehy.2024.111510

Stanić Damić, Marija, et al. "Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams." Medical Hypotheses, vol. 193, 2024. https://doi.org/10.1016/j.mehy.2024.111510

Stanić Damić, Marija, Toni Valković, Duška Petranović, Andrej Belančić and Zinaida Perić. "Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams." Medical Hypotheses 193 (2024). https://doi.org/10.1016/j.mehy.2024.111510

Stanić Damić, M., et al. (2024) 'Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams', Medical Hypotheses, 193. doi: 10.1016/j.mehy.2024.111510

Stanić Damić M, Valković T, Petranović D, Belančić A, Perić Z. Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams. Medical Hypotheses [Internet]. 2024 December 01 [cited 2024 December 24];193. doi: 10.1016/j.mehy.2024.111510

M. Stanić Damić, T. Valković, D. Petranović, A. Belančić and Z. Perić, "Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams", Medical Hypotheses, vol. 193, December 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:967462. [Accessed: 24 December 2024]

Metadata
Title (english)Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams
AuthorMarija Stanić Damić
AuthorToni Valković
AuthorDuška Petranović
AuthorAndrej Belančić
AuthorZinaida Perić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Pharmacology and Toxicology
Abstract (english)
Multiple myeloma is a chronic hematological malignancy that usually affects older adults. Cancer-related cognitive impairment in multiple myeloma patients significantly impacts the everyday quality of life, however its pathophysiology remains poorly understood. Bortezomib is a commonly used drug in the treatment of multiple myeloma that does not pass the blood–brain barrier. Nevertheless, it can still affect central nervous system (CNS) through yet unknown mechanisms. This article discusses the potential effect of bortezomib-based treatment on cognitive functions in multiple myeloma patients. We hypothesize that bortezomib impairs cognition by decreasing the levels of a neuroprotective cytokine – vascular endothelial growth factor (VEGF). The generation of hypotheses about the pathophysiology of cognitive impairment paves the way for future basic and clinical studies to improve multiple myeloma management. VEGF could serve as a biomarker of cognitive dysfunction while systematic evaluation of cognition could enable early detection of cognitive impairment. Timely recognition of cognitive impairment might be crucial when selecting the most appropriate treatment. Furthermore, this could allow the implementation of preventive measures against further deterioration in cognitive function and quality of life for patients with multiple myeloma.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleMedical Hypotheses
Numberingvol. 193, 111510
p-ISSN0306-9877
DOIhttps://doi.org/10.1016/j.mehy.2024.111510
URN:NBNurn:nbn:hr:184:967462
Publication2024-12-01
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0306987724002536
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-12-04 11:45:36